FilingSEC EDGAR6-K
Kazia Therapeutics Reports Paxalisib Preclinical Data and Expands Clinical Trials
· SEC accepted
StagePhase 2 Preparation
Filing content
Kazia Therapeutics announced preclinical data for paxalisib in colorectal and breast cancer and plans to expand its clinical trials based on these findings.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…